Across TCGA pan-cancer cohorts, LINC02155 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC02155’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where LINC02155 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02155 is over-expressed in tumor.
LUAD are the cancer types where LINC02155 tumor–normal differential expression is most reproducible.